Sinco Pharmaceuticals Holdings Limited provides group earnings guidance for the year ended 31 December 2022. For the year, the group is expected to record a net profit attributable to equity holders of the Company for the Current Year of approximately RMB 68.0 million, representing a decrease of approximately RMB 67.1 million or approximately 49.7%, as compared to the net profit attributable to equity holders of the Company of approximately RMB 135.1 million for the year ended 31 December 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.237 HKD | 0.00% | +3.95% | -1.25% |
1st Jan change | Capi. | |
---|---|---|
-1.25% | 61.76M | |
+21.93% | 73.38B | |
-1.71% | 24.13B | |
+7.33% | 8.78B | |
+10.34% | 8.59B | |
-19.80% | 8.06B | |
+14.16% | 5.26B | |
-0.03% | 4.21B | |
+12.70% | 4.17B | |
-2.54% | 3.89B |
- Stock Market
- Equities
- 6833 Stock
- News Sinco Pharmaceuticals Holdings Limited
- Sinco Pharmaceuticals Holdings Limited Provides Group Earnings Guidance for the Year Ended 31 December 2022